Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04060407
Title CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI)
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors OncoImmune, Inc.
Indications

colorectal carcinoma

melanoma

renal cell carcinoma

Therapies

CD24Fc + Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.